NRx Pharmaceuticals, Inc.
NASDAQ:NRXPBiotechnology
+$0.06 today
- Market cap
- $124.12M
- Beta
- 2.19
- P/E (TTM)
- -5.3
- EPS (TTM)
- -$0.76
Volume 2.09M
Average 1.27M
NRXP Total Non-current Liabilities
All obligations due after more than one year.
NRx Pharmaceuticals, Inc.NASDAQ: NRXP
Total Non-current Liabilities · Q1 FY2026 · quarter ended Mar 2026
Total non-current liabilities remains negative
Q1 FY2026 total non-current liabilities was $543K, compared with $0 a year earlier. Over 3 fiscal years it compounded at -51.9% a year.
Context
- Total non-current liabilities amounted to 4.6% of total assets at the end of Q1 FY2026, up 4.6 pp from a year earlier.
- Total non-current liabilities increased in 1 of the last 3 fiscal years.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Non-current Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 315K USD
- Year-over-year change
- -93.7%
| Period | Period end | Total Non-current Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 315K | -93.7% |
| FY2024 | 2024-12-31 | 5.01M | — |
| FY2023 | 2023-12-31 | 0 | -100.0% |
| FY2022 | 2022-12-31 | 2.82M | — |
| FY2021 | 2021-12-31 | 0 | — |
Total Non-current Liabilities vs competitors
How NRXP compares with its peers on the latest reported figures
- NRXP's Mar 2026 total non-current liabilities of $543K is the 6th highest of the 9 companies compared; the peer median is $5.81M.
- Total non-current liabilities amounts to 4.6% of total assets for NRXP, versus a peer median of 10.4%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $279.76M | +15.0% | +0.0% | 212.9% | |
| Mar 2026 | $48.24M | -20.5% | -33.9% | 14.8% | |
| Mar 2026 | $12M | -55.1% | +332.2% | 54.8% | |
| Mar 2026 | $9.73M | +1377.1% | -55.4% | 17.3% | |
| Mar 2026 | $1.88M | +967.0% | -45.4% | 6.1% | |
| Mar 2026 | $543K | — | -51.9% | 4.6% | |
| Mar 2026 | $251K | +68.5% | -70.9% | 0.4% | |
| Jun 2026 | $0 | -100.0% | -15.3% | 0.0% | |
| Mar 2026 | $0 | -100.0% | -37.3% | 0.0% | |
| Peer median (excluding NRXP) | $5.81M | -2.7% | -35.6% | 10.4% | |
Competitors are the stored peer set for NRXP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
NRx Pharmaceuticals, Inc.
NASDAQ:NRXP
Intrinsic Alpha fair value
Locked
Current Price
$2.80
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.